A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT ID: NCT06065748
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
1050 participants
INTERVENTIONAL
2023-12-11
2029-02-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT07100106
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
NCT05638594
NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer
NCT06259929
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Giredestrant + Investigator's Choice of CDK4/6i
Participants in the experimental arm will receive giredestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Giredestrant
Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
Abemaciclib
If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.
Palbociclib
If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
Ribociclib
If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
LHRH Agonist
Only pre/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer on Day 1 of each 28-day treatment cycle.
FoundationOne Liquid CDx Assay (F1LCDx)
F1LCDx is a next-generation sequencing (NGS)-based in vitro diagnostic test that detects and analyses genomic alterations in circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. It will be used to determine the eligibility of participants requiring confirmation of ESR1 mutation status (mutation detected \[ESR1m\] vs. no mutation detected \[ESR1nmd\]).
Fulvestrant + Investigator's Choice of CDK4/6i
Participants in the control arm will receive fulvestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.
Fulvestrant
Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.
Abemaciclib
If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.
Palbociclib
If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
Ribociclib
If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
LHRH Agonist
Only pre/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer on Day 1 of each 28-day treatment cycle.
FoundationOne Liquid CDx Assay (F1LCDx)
F1LCDx is a next-generation sequencing (NGS)-based in vitro diagnostic test that detects and analyses genomic alterations in circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. It will be used to determine the eligibility of participants requiring confirmation of ESR1 mutation status (mutation detected \[ESR1m\] vs. no mutation detected \[ESR1nmd\]).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Giredestrant
Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
Fulvestrant
Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.
Abemaciclib
If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.
Palbociclib
If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
Ribociclib
If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
LHRH Agonist
Only pre/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer on Day 1 of each 28-day treatment cycle.
FoundationOne Liquid CDx Assay (F1LCDx)
F1LCDx is a next-generation sequencing (NGS)-based in vitro diagnostic test that detects and analyses genomic alterations in circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. It will be used to determine the eligibility of participants requiring confirmation of ESR1 mutation status (mutation detected \[ESR1m\] vs. no mutation detected \[ESR1nmd\]).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented estrogen receptor-positive (ER+), HER2-negative (HER2-) tumor assessed locally on the most recent tumor biopsy (or an archived tumor sample if a recent tumor sample is not available for testing)
* Confirmed ESR1 mutation status (ESR1m versus ESR1nmd) in baseline circulating tumor DNA (ctDNA) through central laboratory testing
* Resistance to prior adjuvant endocrine therapy (ET), which is defined as having relapsed with prior standard adjuvant ET, on-treatment after \>/=12 months or off-treatment within 12 months of completion. Prior use of adjuvant CDK4/6i is allowed (if relapse occurred \>/=12 months since completion).
* No prior systemic anti-cancer therapy for advanced disease
* Measurable disease as defined per RECIST v.1.1 or non-measurable (including bone-only) disease
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1
* For pre/perimenopausal women and for men: willing to undergo and maintain treatment with approved LHRH agonist therapy (as per local guidelines) for the duration of study treatment
Exclusion Criteria
* Prior treatment with another SERD (e.g., fulvestrant, oral SERDs) or novel ER-targeting agents
* Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term
* Active cardiac disease or history of cardiac dysfunction
* Clinically significant history of liver disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southern Cancer Center
Daphne, Alabama, United States
Sutter Auburn Faith Hospital
Auburn, California, United States
La Hematology Oncology Medical Group
Glendale, California, United States
Marin Cancer Care Inc
Greenbrae, California, United States
Kaiser Permanente - Harbor City
Harbor City, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
USC Norris Cancer Center
Newport Beach, California, United States
Sutter Medical Group, Roseville Clinic
Roseville, California, United States
Sutter Health Medical Center
Sacramento, California, United States
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente
Torrance, California, United States
Rocky Mountain Cancer Centers
Littleton, Colorado, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
MedStar Washington Hosp Center
Washington D.C., District of Columbia, United States
AdventHealth Altamonte
Altamonte Springs, Florida, United States
Florida Cancer Specialists - Broadway
Fort Myers, Florida, United States
Cancer Specialists of North Florida
Jacksonville, Florida, United States
Comprehensive Hematology Oncology
St. Petersburg, Florida, United States
Florida Cancer Specialists - Tampa
Tampa, Florida, United States
Florida Cancer Specialists - EAST - SCRI - PPDS
West Palm Beach, Florida, United States
Grady Health System
Atlanta, Georgia, United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Advocate Lutheran General Hospital
Park Ridge, Illinois, United States
Springfield Clinic
Springfield, Illinois, United States
Mission Cancer + Blood - IMMC
Des Moines, Iowa, United States
Baptist Health Lexington
Lexington, Kentucky, United States
Baptist Health Hamburg
Lexington, Kentucky, United States
Baptist Health Louisville
Louisville, Kentucky, United States
New England Cancer Specialists
Scarborough, Maine, United States
Maryland Oncology Hematology
Annapolis, Maryland, United States
Frederick Health Hospital
Frederick, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Henry Ford Hospital
Detroit, Michigan, United States
HCA Midwest Division
Kansas City, Missouri, United States
Cancer Care Center of O'Fallon
O'Fallon, Missouri, United States
Oncology Hematology West - Grand Island
Grand Island, Nebraska, United States
Oncology Hematology West - Legacy
Omaha, Nebraska, United States
Astera Cancer Care East Brunswick
East Brunswick, New Jersey, United States
Capital Health Regional Medical Center
Pennington, New Jersey, United States
Queens Hospital Cancer Center
Jamaica, New York, United States
Duke Women Cancer Care
Raleigh, North Carolina, United States
Oncology Hematology Care
Cincinnati, Ohio, United States
Asante Rogue Regional Medical Center
Medford, Oregon, United States
Alliance Cancer Specialists
Bensalem, Pennsylvania, United States
Ann B. Barshinger Cancer Institute
Lancaster, Pennsylvania, United States
Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit
Philadelphia, Pennsylvania, United States
WellSpan Oncology Research
York, Pennsylvania, United States
Brown University Health
Providence, Rhode Island, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Avera Cancer Institute - Aberdeen
Aberdeen, South Dakota, United States
Avera Cancer Institute
Sioux Falls, South Dakota, United States
West Cancer Center
Germantown, Tennessee, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
Texas Oncology Cancer Center
Austin, Texas, United States
JPS Oncology & Infusion Center
Fort Worth, Texas, United States
Texas Oncology - DFW
Irving, Texas, United States
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States
Virginia Commonwealth University - Massey Cancer Center
Richmond, Virginia, United States
Northwest Medical Specialties
Tacoma, Washington, United States
West Virginia University Hospitals Inc
Morgantown, West Virginia, United States
Aurora BayCare Medical Center
Green Bay, Wisconsin, United States
Aurora St Lukes Medical Center
Milwaukee, Wisconsin, United States
Centro de Investigaciones Médicas y Desarrollo LC S.R.L
Buenos Aires, , Argentina
Inst. de Oncologia Angel H. Roffo
Buenos Aires, , Argentina
Centro Oncologico Korben
Ciudad Autonoma Buenos Aires, , Argentina
Sanatorio Allende
Córdoba, , Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, , Argentina
Hospital Alemán
Recoleta, , Argentina
Instituto de Oncología de Rosario
Rosario, , Argentina
Sanatorio Parque S.A.
Rosario, , Argentina
Hospital Provincial del Centenario
Rosario, , Argentina
Centro Oncológico de Excelencia
San Juan, , Argentina
Northern Beaches Hospital
Frenchs Forest, New South Wales, Australia
Nepean Hospital
Kingswood, New South Wales, Australia
Mater Hospital
North Sydney, New South Wales, Australia
University of the Sunshine Coast
Sippy Downs, Queensland, Australia
Mater Misericordiae Limited
South Brisbane, Queensland, Australia
Cancer Research SA
Adelaide, South Australia, Australia
Barwon Health
Geelong, Victoria, Australia
Sunshine Hospital
St Albans, Victoria, Australia
South West Healthcare
Warrnambool, Victoria, Australia
Lkh-Univ. Klinikum Graz
Graz, , Austria
Medical University Innsbruck
Innsbruck, , Austria
Ordensklinikum Linz Barmherzige Schwestern
Linz, , Austria
Oö. Gesundheits- und Spitals-AG/LKH Steyr
Steyr, , Austria
Medizinische Universität Wien
Vienna, , Austria
Cliniques Universitaires St-Luc
Brussels, , Belgium
GHdC Site Les Viviers
Charleroi, , Belgium
UZ Gent
Ghent, , Belgium
UZ Leuven Gasthuisberg
Leuven, , Belgium
CHU de Liège (Sart Tilman)
Liège, , Belgium
AZ St Maarten Campus Leopoldstr
Mechelen, , Belgium
Clinique Ste-Elisabeth
Namur, , Belgium
ZAS Sint Augustinus Wilrijk
Wilrijk, , Belgium
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
CEDOES - Diagnóstico e Pesquisa
Vitória, Espírito Santo, Brazil
Obras Sociais Irma Dulce - Osid
Salvador, Estado de Bahia, Brazil
Hospital Sírio-Libanês
Brasília, Federal District, Brazil
Hospital Araujo Jorge
Goiânia, Goiás, Brazil
Hospital Sao Domingos
São Luís, Maranhão, Brazil
Hospital do Câncer de Londrina
Londrina, Paraná, Brazil
Hospital do Cancer de Pernambuco - HCP
Recife, Pernambuco, Brazil
Vencer Oncoclínica - Centro de Pesquisa do Piauí
Teresina, Piauí, Brazil
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, Brazil
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Hospital Amaral Carvalho
Jaú, São Paulo, Brazil
Hospital Sírio-Libanês
São Paulo, São Paulo, Brazil
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
São Paulo, São Paulo, Brazil
Hospital A. C. Camargo
São Paulo, São Paulo, Brazil
Instituto D'Or de Pesquisa e Ensino
Rio de Janeiro, , Brazil
Cross Cancer Institute
Edmonton, Alberta, Canada
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada
Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre
Mississauga, Ontario, Canada
Lakeridge Health Oshawa
Oshawa, Ontario, Canada
Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, Canada
North York General Hospital
Toronto, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
CIUSSS du Saguenay Lac-Saint-Jean, Chicoutimi Hospital
Chicoutimi, Quebec, Canada
CISSS Chaudière-Appalaches
Lévis, Quebec, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada
McGill University Health Centre - Glen Site
Montreal, Quebec, Canada
CHU de Québec - Hôpital du Saint-Sacrement
Québec, Quebec, Canada
Hopital regional de saint jerome
Saint-Jérôme, Quebec, Canada
Centre hospitalier regional de Trois-Rivieres
Trois-Rivières, Quebec, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Hospital las Higueras
Concepción, Región Bio Bio, Chile
Centro de Oncología de Precisión
Las Condes, , Chile
Clínica Puerto Montt
Port Montt, , Chile
Oncovida
Providencia, , Chile
Centro De Cancer Universidad Catolica
Santiago, , Chile
Instituto Nacional del Cancer
Santiago, , Chile
Icegclinic
Santiago, , Chile
Beijing Cancer Hospital
Beijing, , China
the First Hospital of Jilin University
Changchun, , China
Hunan Cancer Hospital
Changsha, , China
West China Hospital of Sichuan University
Chengdu, , China
Sichuan Provincial People's Hospital
Chengdu, , China
The First Affiliated Hospital, Chongqing Medical University
Chongqing, , China
Fujian Medical University Union Hospital
Fuzhou, , China
No. 900 Hospital (Fuzhou General Hospital)
Fuzhou, , China
Cancer Center, Sun Yat-sen University of Medical Sciences
Guangzhou, , China
The Second Affiliated Hospital of Zhejiang University College
Hangzhou, , China
Harbin Medical University Cancer Hospital
Harbin, , China
Jinan Central Hospital
Jinan, , China
Shandong Cancer Hospital
Jinan, , China
The First People's Hospital of Yunnan Province
Kunming, , China
The First Affiliated Hospital to Henan University of Science and Technology
Luoyang, , China
Guangxi Cancer Hospital of Guangxi Medical University
Nanning, , China
Zhongshan Hospital Fudan University
Shanghai, , China
Fudan University Shanghai Cancer Center
Shanghai, , China
Shanxi Province Cancer Hospital
Taiyuan, , China
Taizhou Hospital of Zhejiang Province
Taizhou, , China
Tianjin Cancer Hospital
Tianjin, , China
The Tumor Hospital of Xinjiang Medical University
Ürümqi, , China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, , China
Hubei Cancer Hospital
Wuhan, , China
The Second Affiliated Hospital of Xi'an Jiao Tong University
Xi'an, , China
Xi'an International Medical Center Hospital
Xi'an, , China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, , China
Zhejiang Cancer Hospital
Zhejiang, , China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, , China
Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
Bogota, D.C., , Colombia
Clinica Colsanitas S.A. sede Clinica Universitaria Colombia
Bogotá D.C., , Colombia
IPS Salud SURA Chipichape Cali
Cali, , Colombia
Oncomedica S.A.
Montería, , Colombia
Sociedad de Oncología y hematología del Cesar Ltda
Valledupar, , Colombia
Clinica CIMCA
San José, , Costa Rica
ICIMED Instituto de Investigación en Ciencias Médicas
San José, , Costa Rica
Proclinical Pharma
San José, , Costa Rica
Kuopio Uni Hospital
Kuopio, , Finland
Tampere University Hospital
Tampere, , Finland
ICO Paul Papin
Angers, , France
Institut Sainte Catherine
Avignon, , France
Hopital Jean Minjoz
Besançon, , France
Centre Francois Baclesse
Caen, , France
Centre Jean Perrin
Clermont-Ferrand, , France
Centre Hospitalier Saint Louis
La Rochelle, , France
Centre Oscar Lambret
Lille, , France
Centre Leon Berard
Lyon, , France
Centre Cancerologie Grand Montpellier
Montpellier, , France
Institut Jean Godinot
Reims, , France
Centre Eugene Marquis
Rennes, , France
IUCT Oncopole
Toulouse, , France
Gustave Roussy
Villejuif, , France
Sozialstiftung Bamberg, Klinikum am Bruderwald, Gynäkologie
Bamberg, , Germany
St. Elisabeth Krankenhaus Köln GmbH
Cologne, , Germany
DONAU ISAR Klinikum Deggendorf
Deggendorf, , Germany
Gynonco Düsseldorf, MVZ Medical Center GmbH
Düsseldorf, , Germany
Universitätsklinikum Erlangen
Erlangen, , Germany
Kliniken Essen-Mitte
Essen, , Germany
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
Freiburg im Breisgau, , Germany
Nationales Centrum für Tumorerkrankungen (NCT)
Heidelberg, , Germany
Universitätsklinikum des Saarlandes
Homburg/Saar, , Germany
Brustzentrum Rhein-Ruhr Servicegesellschaft mbH
Mönchengladbach, , Germany
Rotkreuzklinikum München
München, , Germany
Anticancer Hospital Ag. Savas
Athens, , Greece
Aretaieio Hospital of Athens
Athens, , Greece
University Hospital of Larissa
Larissa, , Greece
University Hospital of Patras Medical Oncology
Pátrai, , Greece
European Interbalkan Medical Center
Thessaloniki, , Greece
Oncomedica
Guatemala City, , Guatemala
Celan S.A.
Guatemala City, , Guatemala
INTEGRA Cancer Institute
Guatemala City, , Guatemala
Onco Go, S.A.
Guatemala City, , Guatemala
Grupo Angeles
Guatemala City, , Guatemala
Medi-k
Guatemala City, , Guatemala
Centro Medico Integral de Cancerologia CEMIC
Salcajá, , Guatemala
Pamela Youde Nethersole Eastern Hospital
Hong Kong, , Hong Kong
Queen Mary Hospital
Hong Kong, , Hong Kong
Orszagos Onkologiai Intezet
Budapest, , Hungary
Bács-Kiskun Vármegyei Oktatókórház
Kecskemét, , Hungary
B-A-Z Vármegyei Központi Kórház és Egyetemi Oktatókórház
Miskolc, , Hungary
Nograd Varmegyei Szent Lazar Korhaz
Salgótarján, , Hungary
HealthCare Global Enterprises Limited
Banglore, Karnataka, India
MVR Cancer Centre and Research Institute
Kozhikode, Kerala, India
Regional Cancer Centre
Trivandrum, Kerala, India
Sir H. N. Reliance Foundation Hospital and Research Centre
Mumbai, Maharashtra, India
Grant Medical Foundation, Ruby Hall Clinic
Pune, Maharashtra, India
Sahyadri Speciality Hospital
Pune, Maharashtra, India
Sunact Cancer Institute
Thane, Maharashtra, India
Max Super Speciality Hospital
New Delhi, National Capital Territory of Delhi, India
Hadassah Ein Karem Hospital
Jerusalem, , Israel
Rabin Medical Center
Petah Tikva, , Israel
Sheba MC
Ramat Gan, , Israel
Sourasky Medical Center
Tel Aviv, , Israel
Presidio Ospedaliero di Summa-Perrino
Brindisi, Apulia, Italy
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati
Avellino, Campania, Italy
Azienda Ospedaliera Universitaria Federico II
Napoli, Campania, Italy
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE
Napoli, Campania, Italy
Policlinico S.Orsola-Malpighi
Bologna, Emilia-Romagna, Italy
I.R.S.T Srl IRCCS
Meldola, Emilia-Romagna, Italy
A.O. Universitaria Di Parma
Parma, Emilia-Romagna, Italy
RCCS - Centro di Riferimento
Aviano (PN), Friuli Venezia Giulia, Italy
A.O. Universitaria S. Maria Della Misericordia Di Udine
Udine, Friuli Venezia Giulia, Italy
Policlinico Universitario Agostino Gemelli
Rome, Lazio, Italy
Università Campus Bio-Medico di Roma
Rome, Lazio, Italy
Asst Papa Giovanni XXIII
Bergamo, Lombardy, Italy
Asst Degli Spedali Civili Di Brescia
Brescia, Lombardy, Italy
Asst Di Cremona
Cremona, Lombardy, Italy
Irccs Istituto Nazionale Dei Tumori (Int)
Milan, Lombardy, Italy
Istituto Clinico Humanitas
Rozzano, Lombardy, Italy
A.O.U. Maggiore della Carità
Novara, Piedmont, Italy
Humanitas Centro Catanese Di Oncologia
Misterbianco (CT), Sicily, Italy
Ospedale Di Macerata
Macerata, The Marches, Italy
Azienda Ospedaliera Universitaria Careggi
Florence, Tuscany, Italy
IOV - Istituto Oncologico Veneto - IRCCS
Padua, Veneto, Italy
University of Nairobi - Institute of Tropical and Infectious Diseases
Nairobi, , Kenya
Panamerican Clinical Research S.A de C.V.
Guadalajara, Jalisco, Mexico
RENATI INNOVATION S.A.P.I. de C.V
Guadalajara, Jalisco, Mexico
Productos y Servicios Oncologicos Acacias SA de CV
Mexico City, Mexico CITY (federal District), Mexico
Centro de Atencion Oncologica Viva S de RL de CV
Mexico City, Mexico CITY (federal District), Mexico
Hospital Zambrano Hellion TecSalud
Monterrey, Nuevo León, Mexico
Centro de Investigacion Clinica de Oaxaca
Oaxaca City, Oaxaca, Mexico
PanAmerican Clinical Research, Querétaro
Queréaro, Querétaro, Mexico
CENEIT Oncologicos
Mexico City, , Mexico
Clinica Alivia sucursal Coyoacan
Mexico City, , Mexico
Christchurch Hospital
Christchurch, , New Zealand
Palmerston North Hospital
Palmerston North, , New Zealand
Whangarei Hospital
Whangarei, , New Zealand
Centro Medico Monte Carmelo
Arequipa, , Peru
Hospital Goyeneche
Arequipa, , Peru
Clínica Santa Beatriz
Lima, , Peru
Hospital Nacional Arzobispo Loayza
Lima, , Peru
Oncosalud Sac
Lima, , Peru
Instituto Nacional de Enfermedades Neoplasicas
Lima, , Peru
Clinica Internacional, Sede San Borja
Lima, , Peru
Instituto Peruano de Oncología y Radioterapia
Lima, , Peru
Clinica San Antonio;Investigaciones Trujillo S.A.C.
Trujillo, , Peru
Clinica Peruana Americana
Trujillo, , Peru
Instituto Regional de Enfermedades Neoplasicas - IREN Norte
Trujillo, , Peru
Instytut "Centrum Zdrowia Matki Polki"
?ód?, , Poland
Centrum Onkologii im. Prof. Franciszka ?ukaszczyka
Bydgoszcz, , Poland
Szpital Morski Im. Pck
Gdynia, , Poland
Narodowy Instytut Onkologii Odzia? w Gliwicach
Gliwice, , Poland
?wi?tokrzyskie Centrum Onkologii
Kielce, , Poland
Przychodnia Lekarska KOMED, Roman Karaszewski
Konin, , Poland
Szpital Wojewódzki im. Miko?aja Kopernika
Koszalin, , Poland
Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli
Lublin, , Poland
Opolskie Centrum Onkologii
Opole, , Poland
Mazowiecki Szpital Wojewódzki im. ?w. Jana Paw?a II
Siedlce, , Poland
Zachodniopomorskie Centrum Onkologii
Szczecin, , Poland
Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad
Warsaw, , Poland
IPO de Coimbra
Coimbra, , Portugal
Hospital de S. Francisco Xavier
Lisbon, , Portugal
Hospital da Luz
Lisbon, , Portugal
IPO do Porto
Porto, , Portugal
CHVNG/E_Unidade 1
Vila Nova de Gaia, , Portugal
PanOncology Trials
San Juan, , Puerto Rico
Spitalul Clinic Filantropia
Bucharest, , Romania
Institutul Oncologic Prof. Dr. Alexandru Trestioreanu
Bucharest, , Romania
Amethyst Cluj
Cluj County, , Romania
Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca
Cluj-Napoca, , Romania
Centrul de Oncologie Sfantul Nectarie
Craiova, , Romania
Institutul Regional de Oncologie Iasi
Iași, , Romania
Centrul de Oncologie Oncohelp
Timișoara, , Romania
National University Hospital
Singapore, , Singapore
National Cancer Centre
Singapore, , Singapore
Icon Cancer Centre Gleneagles
Singapore, , Singapore
Institute of Oncology Ljubljana
Ljubljana, , Slovenia
Cancercare Rondebosch Oncology
Cape Town, , South Africa
Cancercare
Port Elizabeth, , South Africa
Steve Biko Academic Hospital
Pretoria, , South Africa
Kyungpook National University Chilgok Hospital
Daegu, , South Korea
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Korea University Anam Hospital
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Gangnam Severance Hospital
Seoul, , South Korea
Ewha Womans University Mokdong Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Ulsan University Hosiptal
Ulsan, , South Korea
Institut Catala d?Oncologia Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital de Jerez de la Frontera
Jerez de la Frontera, Cadiz, Spain
Hospital Quiron de Madrid
Pozuelo de Alarcón, Madrid, Spain
Hospital Universitario Virgen de La Arrixaca
EL Palmar (EL Palmar), Murcia, Spain
Hospital Alvaro Cunqueiro
Vigo, Pontevedra, Spain
Hospital Universitari Dexeus - Grupo Quironsalud
Barcelona, , Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Juan Ramon Jimenez
Huelva, , Spain
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico
Jaén, , Spain
Centro Oncologico MD Anderson Internacional
Madrid, , Spain
Hospital de Madrid Norte Sanchinarro- Centro Integral Oncologico Clara Campal
Madrid, , Spain
Hospital Universitario Virgen Macarena
Seville, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Instituto Valenciano Oncologia
Valencia, , Spain
Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia
Valencia, , Spain
Hsin-Chu Branch of National Taiwan University Hospital
Hsinchu, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
Veterans General Hospital
Taipei, , Taiwan
National Taiwan Uni Hospital
Taipei, , Taiwan
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, , Taiwan
Veterans General Hospital - Taichung
Xitun Dist., , Taiwan
Chulalongkorn Hospital
Bangkok, , Thailand
National Cancer Institute
Bangkok, , Thailand
Rajavithi Hospital
Bangkok, , Thailand
Chulabhorn Hospital
Lak Si, , Thailand
Maharaj Nakorn Chiang Mai Hospital;Depart of Radiology
Muang Chiang MAI Delivery Branch 3, , Thailand
Songklanagarind Hospital
Songkhla, , Thailand
Sakarya Training and Research Hospital
Adapazarı, , Turkey (Türkiye)
Ankara City Hospital
Ankara, , Turkey (Türkiye)
Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji
Bakirkoy / Istanbul, , Turkey (Türkiye)
Katip Celebi University Ataturk Training and Research Hospital
Izmir, , Turkey (Türkiye)
Goztepe Prof.Dr. Suleyman Yalcin City Hospital
Kadiköy, , Turkey (Türkiye)
Mersin City Education and Research Hospital
Mersin, , Turkey (Türkiye)
Medikal Park Samsun
Samsun, , Turkey (Türkiye)
Hacettepe Uni Medical Faculty Hospital
Sihhiye/Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Reference Study ID Number: CO44657 https://forpatients.roche.com/
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-502980-39-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
CO44657
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.